Shanghai Yaoda Biotechnology

Shanghai Yaoda Biotechnology is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the development of innovative chimeric antigen receptor T-cell (CAR-T) therapies. The company focuses on addressing unmet medical needs in hematological malignancies and solid tumors through its proprietary cell engineering and manufacturing platforms. Its lead program, YD-001, is an autologous CAR-T therapy targeting CD19 for the treatment of B-cell lymphoma and acute lymphoblastic leukemia. Additionally, the company is advancing YD-002, a BCMA-targeted CAR-T for multiple myeloma, and exploring multi-target CAR-T designs. Yaoda Biotechnology operates a GMP-compliant facility to support its clinical development and future commercialization efforts.